retatrutide trial sign up ESC 2024: improves lipid and cardiovascular risk profile in Phase II Triple hormone receptor agonist retatrutide

If you or someone you know is living with substance use disorder, free, confidential help is available 24 hours a day, seven days a week, by calling or texting the national lifeline at 988

To view or add a comment, sign in CareSet's latest analysis "Hospital Corporations vs

What insurance plans cover weight loss medication under Medicaid depends entirely on whether the state has elected to include anti-obesity medications in its preferred drug list

14.6% of the participants qualified for participation based on elevated filling pressures, 13.4% based on hospitalization for heart failure within 12 months in combination with ongoing diuretic treatment or echocardiographic abnormalities (or both), and 72.0% based on NT-proBNP levels plus echocardiographic abnormalities Median body weight and BMI of participants were 105.1 kg and 37.0kg/m 2 , respectively At baseline, patients had substantial degree of heart failure related symptoms, physical limitations, and poor exercise tolerance Outcomes Primary Outcome Co-primary endpoints for Semaglutide vs placebo from baseline to week 52: Change in KCCQ-CSS 16.6 points vs 8.7 points (estimated difference, 7.8 points

Realistic expectations, always Weight loss takes time

The PRISMA flow diagram (Figure 1) outlines the selection process